Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 11/20 | 0.74 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.51 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.51 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.47 |
| ▸ | EDNRB | P24530 | 2/20 | 0.47 |
| ▸ | EDNRA | P25101 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CCR4 | P51679 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3934777 | 0.88 | HSD11B1 (0.72) | HSD11B1HSD17B1HSD17B2SLC40A1EDNRB | |
| SCHEMBL3934250 | 0.86 | HSD11B1 (0.70) | HSD11B1HSD17B1HSD17B2SLC40A1EDNRB | |
| SCHEMBL5693072 | 0.86 | HSD11B1 (0.76) | HSD11B1HSD17B1HSD17B2SLC40A1EDNRB | |
| SCHEMBL3925757 | 0.86 | HSD11B1 (0.72) | HSD11B1HSD17B1HSD17B2SLC40A1EDNRB | |
| SCHEMBL3926760 | 0.85 | HSD11B1 (1.00) | HSD11B1HSD17B1HSD17B2SLC40A1EDNRB | |
| SCHEMBL3935130 | 0.85 | HSD11B1 (0.71) | HSD11B1HSD17B1HSD17B2SLC40A1EDNRB | |
| SCHEMBL27793872 | 0.85 | HSD11B1 (0.76) | HSD11B1HSD17B1HSD17B2SLC40A1EDNRB | |
| SCHEMBL6027116 | 0.84 | HSD11B1 (0.67) | HSD11B1HSD17B1HSD17B2SLC40A1EDNRB | |
| SCHEMBL27660484 | 0.84 | HSD11B1 (0.70) | HSD11B1HSD17B1HSD17B2SLC40A1EDNRB | |
| SCHEMBL3927607 | 0.83 | HSD11B1 (0.68) | HSD11B1HSD17B1HSD17B2SLC40A1EDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1897944-A | Benzenesulfonamido-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD-1) for the treatment of diabetes and obesity | AGOURON PHARMA (US) | 2007-01-17 | — | — | CN | disclosed |
| EP-1696915-A1 | BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY | Pfizer, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| EP-1659113-A1 | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) | Evotec AG (DE) | 2006-05-24 | — | — | EP | disclosed |
| WO-2006050908-A1 | INHIBITORS OF 11ΒΕΤΑ-HYDROXY STEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) | EVOTEC AG (DE) | 2006-05-18 | — | — | WO | disclosed |
| US-20050148631-A1 | Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AGOURON PHARMACEUTICALS, INC. | 2005-07-07 | — | — | US | disclosed |
| WO-2005060963-A1 | BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY | PFIZER INC. (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148631-A1 | Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B11, HSD11B2 | HSD11B1 1/4885HSD17B1 5/4885HSD17B2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.